• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在韩国,当无法获得匹配的国内供体时,医生对于异基因干细胞移植中供体选择的偏好和看法。

Physicians' preferences and perceptions regarding donor selection in allogeneic stem cell transplantation in Korea when a matched domestic donor is not available.

作者信息

Shin Min Kyung, Shin Sangjin, Lee Ja Youn, Koh Youngil

机构信息

National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.

National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

出版信息

Blood Res. 2017 Mar;52(1):31-36. doi: 10.5045/br.2017.52.1.31. Epub 2017 Mar 27.

DOI:10.5045/br.2017.52.1.31
PMID:28401099
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5383585/
Abstract

BACKGROUND

A number of alternative donor options exist for patients who fail to find domestic HLA-matched donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed physicians' perspectives on allo-HSCT donor selection when a matched domestic donor is not available.

METHODS

We administered a questionnaire survey to 55 hematologists (response rate: 28%) who attended the annual spring conference of the Korean Society of Haematology in 2015. The questionnaire contained four clinical allo-HSCT scenarios and the respondents were asked to choose the most preferred donor among the given options.

RESULTS

In all four scenarios, the hematologists preferred a matched international donor over partially mismatched unrelated domestic or haplo-matched family donors. The numbers of hematologists who chose a matched international donor (HLA 8/8) in cases of acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and aplastic anemia were 37 (67.3%), 41 (74.6%), 33 (60.0%), and 36 (65.5%), respectively. The important factors that affected donor selection included "expecting better clinical outcomes (40.5%)" and "lower risk of side effects (23.4%)." The majority of participants (80%) responded that allo-HSCT guidelines for donor selection customized for the Korean setting are necessary.

CONCLUSION

Although hematologists still prefer perfectly matched foreign donors when a fully matched domestic allo-HSCT donor is not available, we confirmed that there was variation in their responses. For evidence-based clinical practice, it is necessary to provide further comparative clinical evidence on allo-HSCT from haplo-matched family donors and fully matched unrelated international donors.

摘要

背景

对于在同种异体造血干细胞移植(allo-HSCT)中未能找到国内HLA匹配供者的患者,存在多种替代供者选择。我们评估了在没有匹配的国内供者时,医生对于allo-HSCT供者选择的观点。

方法

我们对参加2015年韩国血液学会年度春季会议的55名血液科医生进行了问卷调查(回复率:28%)。问卷包含四个临床allo-HSCT场景,要求受访者在给定选项中选择最偏好的供者。

结果

在所有四个场景中,血液科医生更倾向于选择匹配的国际供者,而非部分不匹配的无关国内供者或单倍型匹配的家族供者。在急性髓系白血病、慢性髓系白血病、急性淋巴细胞白血病和再生障碍性贫血病例中,选择匹配的国际供者(HLA 8/8)的血液科医生人数分别为37名(67.3%)、41名(74.6%)、33名(60.0%)和36名(65.5%)。影响供者选择的重要因素包括“期望更好的临床结果(40.5%)”和“副作用风险更低(23.4%)”。大多数参与者(80%)回答说需要针对韩国情况定制的allo-HSCT供者选择指南。

结论

尽管在没有完全匹配的国内allo-HSCT供者时,血液科医生仍然更倾向于完全匹配的国外供者,但我们证实他们的回答存在差异。为了基于证据的临床实践,有必要提供关于单倍型匹配的家族供者和完全匹配的无关国际供者的allo-HSCT的进一步比较临床证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/5383585/5ddd1c19d5bf/br-52-31-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/5383585/ce32143ae1b1/br-52-31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/5383585/5ddd1c19d5bf/br-52-31-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/5383585/ce32143ae1b1/br-52-31-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fb7/5383585/5ddd1c19d5bf/br-52-31-g002.jpg

相似文献

1
Physicians' preferences and perceptions regarding donor selection in allogeneic stem cell transplantation in Korea when a matched domestic donor is not available.在韩国,当无法获得匹配的国内供体时,医生对于异基因干细胞移植中供体选择的偏好和看法。
Blood Res. 2017 Mar;52(1):31-36. doi: 10.5045/br.2017.52.1.31. Epub 2017 Mar 27.
2
HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.HLA 匹配的同胞供者与无关供者和单倍体相合相关供者异基因造血干细胞移植治疗 60 岁以上急性髓系白血病患者:一项单中心供者比较。
Biol Blood Marrow Transplant. 2018 Jul;24(7):1449-1454. doi: 10.1016/j.bbmt.2018.02.002. Epub 2018 Feb 12.
3
[A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].[非血缘供者与同胞全相合供者异基因造血干细胞移植治疗儿童及青少年获得性重型再生障碍性贫血的比较研究]
Zhonghua Nei Ke Za Zhi. 2016 Dec 1;55(12):927-931. doi: 10.3760/cma.j.issn.0578-1426.2016.12.004.
4
Turkish Hematologists’ Preferences for Related Donor Selection: Results of a Multicenter Survey.土耳其血液学家对相关供者选择的偏好:一项多中心调查的结果。
Turk J Haematol. 2024 Aug 28;41(3):182-187. doi: 10.4274/tjh.galenos.2024.2024.0099. Epub 2024 May 27.
5
Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).2011 - 2012年东地中海区域造血干细胞移植:代表东地中海血液与骨髓移植组(EMBMT)的综合报告。
Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):167-75. doi: 10.1016/j.hemonc.2015.09.002. Epub 2015 Oct 1.
6
Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.费城染色体阴性成人急性淋巴细胞白血病的异基因造血干细胞移植:清髓性、非清髓性及其他。
Hematology. 2015 Mar;20(2):61-71. doi: 10.1179/1607845414Y.0000000175. Epub 2014 Jul 3.
7
A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.急性白血病中未处理的单倍体相合供者与无关供者的异基因干细胞移植比较。
J Hematol Oncol. 2017 Jan 19;10(1):24. doi: 10.1186/s13045-017-0394-2.
8
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.来自HLA匹配供者和替代供者的异基因造血干细胞移植的结局:欧洲血液与骨髓移植学会登记处的回顾性分析
Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.
9
[Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].单倍型人类白细胞抗原配型造血干细胞移植治疗恶性血液病的临床研究
Ai Zheng. 2006 Aug;25(8):1019-22.
10
[Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].[41例重型再生障碍性贫血患者接受人类白细胞抗原匹配同胞供者异基因造血干细胞移植的疗效]
Zhonghua Xue Ye Xue Za Zhi. 2012 Aug;33(8):610-4.

本文引用的文献

1
Modern approaches to HLA-haploidentical blood or marrow transplantation.人类白细胞抗原单倍型相合的血液或骨髓移植的现代方法。
Nat Rev Clin Oncol. 2016 Feb;13(2):132. doi: 10.1038/nrclinonc.2015.234. Epub 2015 Dec 31.
2
Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders.异基因造血干细胞移植治疗非恶性血液病。
J Adv Res. 2015 May;6(3):449-58. doi: 10.1016/j.jare.2014.11.001. Epub 2014 Nov 7.
3
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
缓解期 AML 患者接受 HLA 单倍体相合与同胞全相合移植的前瞻性多中心研究
Blood. 2015 Jun 18;125(25):3956-62. doi: 10.1182/blood-2015-02-627786. Epub 2015 May 4.
4
Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.与 HLA 相同的同胞供体移植相比,亲缘单倍体移植治疗高危急性白血病具有更好的移植物抗白血病效应:一项历史性比较。
Biol Blood Marrow Transplant. 2011 Jun;17(6):821-30. doi: 10.1016/j.bbmt.2010.08.023. Epub 2010 Sep 8.
5
Hematopoietic stem cell transplantation for myelodysplastic syndrome.骨髓增生异常综合征的造血干细胞移植。
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S37-44. doi: 10.1016/j.bbmt.2009.10.018. Epub 2009 Oct 24.
6
Allogeneic stem cell transplantation for aplastic anemia.再生障碍性贫血的异基因干细胞移植
Biol Blood Marrow Transplant. 2007 May;13(5):505-16. doi: 10.1016/j.bbmt.2007.02.005.
7
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.预处理包括抗胸腺细胞球蛋白,随后进行未处理的HLA配型不合/单倍型相合的血液和骨髓移植,其疗效可与HLA全相合的同胞移植相媲美。
Blood. 2006 Apr 15;107(8):3065-73. doi: 10.1182/blood-2005-05-2146. Epub 2005 Dec 27.
8
Haploidentical stem cell transplantation: the always present but overlooked donor.单倍体相合干细胞移植:始终存在却被忽视的供者
Hematology Am Soc Hematol Educ Program. 2005:390-5. doi: 10.1182/asheducation-2005.1.390.
9
Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies.血红蛋白病造血干细胞移植无关供者的可及性
Bone Marrow Transplant. 2003 Apr;31(7):547-50. doi: 10.1038/sj.bmt.1703887.
10
Feasibility of finding an unrelated bone marrow donor on international registries for New Zealand patients.新西兰患者在国际骨髓捐献者登记处寻找非亲属骨髓捐献者的可行性。
Bone Marrow Transplant. 1999 Feb;23(3):291-4. doi: 10.1038/sj.bmt.1701561.